Elevance Health, Inc.
Elevance Health, Inc. (ELV) Stock News
The latest ELV headlines and market coverage — 3 recent stories, updated throughout the day.
- Zacks Investment Research·
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
Smith+Nephew (SNN) launched the EVOS PELVIC Plating System to expand its orthopedic trauma portfolio into pelvic and acetabular fracture management. The system features dedicated plates, cannulated screws, and specialized instruments designed to improve surgical efficiency. The global pelvic trauma market is projected to grow from $2.81 billion in 2025 to $4.79 billion by 2034 at a 6.1% CAGR, driven by increased high-energy fractures and wider adoption of surgical fixation protocols.
- Zacks Investment Research·
ELV or DHR: Which Is the Better Value Stock Right Now?
In a comparison of two Medical Services stocks, Elevance Health (ELV) emerges as the superior value option over Danaher (DHR). ELV holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 15.70 and PEG ratio of 2.22. DHR has a Zacks Rank of #3 (Hold) with a Value grade of D, with a forward P/E of 23.84 and PEG ratio of 2.53. Based on valuation metrics and earnings outlook, ELV is positioned as the better value investment.
- The Motley Fool·Neutral
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?
OrbiMed Advisors, a major shareholder owning over 10% of Enliven Therapeutics, sold 281,408 shares for approximately $12.7 million on June 15, 2026. Despite the company's recent positive Phase III leukemia drug trial data and 95% one-year stock price gain, the insider sale raises questions about whether the hedge fund views the recent rally as a peak opportunity to take profits, though the sale could also reflect routine portfolio rebalancing.